[1] KAY N E, HAMPEL P J, VAN DYKE D L, et al. CLL update 2022: a continuing evolution in care[J]. Blood Rev, 2022, 54: 100930. doi:  10.1016/j.blre.2022.100930
[2] SMALL S, MA S. Frontline treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL): targeted therapy vs. chemoimmunotherapy[J]. Curr Hematol Malig Rep, 2021, 16(4): 325-335. doi:  10.1007/s11899-021-00637-1
[3] ZI F M, YU L, SHI Q Z, et al. Ibrutinib in CLL/SLL: from bench to bedside(review)[J]. Oncol Rep, 2019, 42(6): 2213-2227.
[4] BOND D A, WOYACH J A. Targeting BTK in CLL: beyond ibrutinib[J]. Curr Hematol Malig Rep, 2019, 14(3): 197-205. doi:  10.1007/s11899-019-00512-0
[5] RATAIN M J, MOSLEHI J J, LICHTER A S. Ibrutinib’s cardiotoxicity-an opportunity for postmarketing regulation[J]. JAMA Oncol, 2021, 7(2): 177-178. doi:  10.1001/jamaoncol.2020.5742
[6] LAZARUS G, AUDREY J, ISKANDAR A W B. Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review[J]. Oncol Rev, 2019, 13(2): 425. doi:  10.4081/oncol.2019.425
[7] RULE S, JURCZAK W, JERKEMAN M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study[J]. Leukemia, 2018, 32(8): 1799-1803. doi:  10.1038/s41375-018-0023-2
[8] HUANG X J, QIU L G, JIN J, et al. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study[J]. Cancer Med, 2018, 7(4): 1043-1055. doi:  10.1002/cam4.1337
[9] CHANAN-KHAN A, CRAMER P, DEMIRKAN F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study[J]. Lancet Oncol, 2016, 17(2): 200-211. doi:  10.1016/S1470-2045(15)00465-9
[10] BYRD J C, BROWN J R, O’BRIEN S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia[J]. N Engl J Med, 2014, 371(3): 213-223. doi:  10.1056/NEJMoa1400376
[11] DIMOPOULOS M A, TEDESCHI A, TROTMAN J, et al. Phase 3 trial of ibrutinib plus rituximab in waldenström’s macroglobulinemia[J]. N Engl J Med, 2018, 378(25): 2399-2410. doi:  10.1056/NEJMoa1802917
[12] BURGER J A, TEDESCHI A, BARR P M, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med, 2015, 373(25): 2425-2437. doi:  10.1056/NEJMoa1509388
[13] WOYACH J A, RUPPERT A S, HEEREMA N A, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL[J]. N Engl J Med, 2018, 379(26): 2517-2528. doi:  10.1056/NEJMoa1812836
[14] MORENO C, GREIL R, DEMIRKAN F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia(iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(1): 43-56. doi:  10.1016/S1470-2045(18)30788-5
[15] TAM C S, OPAT S, D’SA S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study[J]. Blood, 2020, 136(18): 2038-2050. doi:  10.1182/blood.2020006844
[16] FRASER G, CRAMER P, DEMIRKAN F, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma[J]. Leukemia, 2019, 33(4): 969-980. doi:  10.1038/s41375-018-0276-9
[17] DEEKS E D. Ibrutinib: a review in chronic lymphocytic leukaemia[J]. Drugs, 2017, 77(2): 225-236. doi:  10.1007/s40265-017-0695-3
[18] ALLAN J N, FURMAN R R. Optimal management of the young patient CLL patient[J]. Best Pract Res Clin Haematol, 2018, 31(1): 73-82. doi:  10.1016/j.beha.2017.10.012
[19] SCARFÒ L, FERRERI A J M, GHIA P. Chronic lymphocytic leukaemia[J]. Crit Rev Oncol, 2016, 104: 169-182. doi:  10.1016/j.critrevonc.2016.06.003
[20] KRAUSE D S, VAN ETTEN R A. Tyrosine kinases as targets for cancer therapy[J]. N Engl J Med, 2005, 353(2): 172-187. doi:  10.1056/NEJMra044389
[21] ISOMOTO K, HARATANI K, HAYASHI H, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26(8): 2037-2046. doi:  10.1158/1078-0432.CCR-19-2027
[22] ZHAO J, XU W T, ZHOU F, et al. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC: mechanisms and evolving treatment approaches[J]. Nat Rev Clin Oncol, 2026, 23(1): 63-83. doi:  10.1038/s41571-025-01085-z
[23] DE JONG J, HELLEMANS P, JIAO J J, et al. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study[J]. Cancer Chemother Pharmacol, 2017, 80(6): 1227-1237. doi:  10.1007/s00280-017-3471-x
[24] MULDER T A, PEÑA-PÉREZ L, BERGLÖF A, et al. Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia[J]. Hemasphere, 2021, 5(5): e564. doi:  10.1097/HS9.0000000000000564
[25] JIANG L, LI L L, RUAN Y F, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium[J]. Heart Rhythm, 2019, 16(9): 1374-1382. doi:  10.1016/j.hrthm.2019.04.008
[26] LEONG D P, CARON F, HILLIS C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis[J]. Blood, 2016, 128(1): 138-140. doi:  10.1182/blood-2016-05-712828
[27] FRADLEY M G, GLIKSMAN M, EMOLE J, et al. Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy[J]. Am J Cardiol, 2019, 124(4): 539-544. doi:  10.1016/j.amjcard.2019.05.029
[28] FRADLEY M G, WELTER-FROST A, GLIKSMAN M, et al. Electrocardiographic changes associated with ibrutinib exposure[J]. Cancer Control, 2020, 27(1): 1073274820931808.